Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Change in Account Payables (2020 - 2024)

Historic Change in Account Payables for Relay Therapeutics (RLAY) over the last 5 years, with Q3 2024 value amounting to -$4.3 million.

  • Relay Therapeutics' Change in Account Payables fell 25188.22% to -$4.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$6.4 million, marking a year-over-year decrease of 22870.43%. This contributed to the annual value of -$2.4 million for FY2023, which is 22036.2% down from last year.
  • Relay Therapeutics' Change in Account Payables amounted to -$4.3 million in Q3 2024, which was down 25188.22% from $3.2 million recorded in Q2 2024.
  • Relay Therapeutics' Change in Account Payables' 5-year high stood at $4.6 million during Q3 2022, with a 5-year trough of -$5.4 million in Q4 2023.
  • For the 5-year period, Relay Therapeutics' Change in Account Payables averaged around -$46210.5, with its median value being -$56000.0 (2021).
  • Over the last 5 years, Relay Therapeutics' Change in Account Payables had its largest YoY gain of 82845.91% in 2022, and its largest YoY loss of 595000.0% in 2022.
  • Over the past 5 years, Relay Therapeutics' Change in Account Payables (Quarter) stood at $1.3 million in 2020, then soared by 89.63% to $2.4 million in 2021, then decreased by 19.15% to $2.0 million in 2022, then tumbled by 373.21% to -$5.4 million in 2023, then grew by 19.99% to -$4.3 million in 2024.
  • Its last three reported values are -$4.3 million in Q3 2024, $3.2 million for Q2 2024, and $102000.0 during Q1 2024.